
    
      All the patients will be included in the final analysis, with a total of 48 patients to be
      enrolled.

      Treatment will occur until disease progression, unacceptable toxicity or patient withdrawal.

      Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.

      Response evaluation will be performed every 6 weeks (+/- 1 week window period is allowed).
    
  